Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use
Open Access
- 29 July 2021
- Vol. 9 (8), 836
- https://doi.org/10.3390/vaccines9080836
Abstract
As per the World Health Organization (WHO), more than 288 vaccines against COVID-19 are being developed, with an estimated 184 being presently investigated in the pre-clinical phases, while 104 of these vaccine candidates are at various stages of clinical trials. Twelve of these are in the advanced stages of clinical investigation, and promising results in the phase 3 trials have already paved the way for their regulatory approval and subsequent dissemination for global use. Preliminary and interim results of some of these candidate vaccines are being analyzed for public dissemination. Some of these vaccines have already been rolled out to immunize not only the highest risk individuals but also the general population in several countries. Once their safety and efficacy are established, the next limiting step would be their mass manufacturing by the pharmaceutical companies to fulfill the global demand. The challenge of manufacturing billions of doses of high-quality vaccines is under-appreciated at the moment. A massive vaccination drive would be needed to protect people of all ages. The timely and coordinated execution of the vaccination effort would require unprecedented coordination at the national and international levels for generating funds to purchase the required doses of vaccines, fair distribution of doses and managing the mechanics of delivering vaccines throughout the world.Keywords
This publication has 72 references indexed in Scilit:
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformationScience, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak — Final ReportThe New England Journal of Medicine, 2019
- Single-Dose Cholera Vaccine in Response to an Outbreak in ZambiaThe New England Journal of Medicine, 2018
- Fractional dosing of yellow fever vaccine to extend supply: a modelling studyThe Lancet, 2016
- Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study GroupJournal of Virology, 2013
- Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi ArabiaThe New England Journal of Medicine, 2012
- Intradermally Administered Yellow Fever Vaccine at Reduced Dose Induces a Protective Immune Response: A Randomized Controlled Non-Inferiority TrialPLOS ONE, 2008
- A Novel Coronavirus Associated with Severe Acute Respiratory SyndromeThe New England Journal of Medicine, 2003
- Coronavirus as a possible cause of severe acute respiratory syndromeThe Lancet, 2003